| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184683 | Gynecologic Oncology | 2012 | 11 Pages |
Abstract
⺠This is the first systematic review regarding mTOR inhibitors in breast cancer. ⺠The BOLERO-2 study has marked a turning point regarding everolimus for ER-positive breast cancer. ⺠Everolimus may provide an avenue for achieving long-lasting benefit in HER2-positive patients.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Flora Zagouri, Theodoros N. Sergentanis, Dimosthenis Chrysikos, Martin Filipits, Rupert Bartsch,